Following on from information provided to NICE by the company in December 2020, the appraisal of Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma [ID1610] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1610 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 21 November 2022 | Following on from information provided to NICE by the company in December 2020, the appraisal of Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma [ID1610] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 21 November 2022 | Discontinued. Following on from information provided to NICE by the company in December 2020, the appraisal of Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma [ID1610] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 10 December 2020 | The Department for Health and Social Care has asked NICE to carry out an appraisal of nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma For information, the company have announced that CheckMate -915 did not meet its primary endpoint and therefore they will no longer be pursuing a marketing authorisation application in this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes |
| 10 December 2020 | Suspended. Topic is suspended |
| 13 September 2019 - 11 October 2019 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 09 August 2019 | In progress. Referred 31 July 2017 |
For further information on our processes and methods, please see our CHTE processes and methods manual